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Introduction 
Colorectal  cancer  is  a  common  malignancy  and  the  second 
commonest cause of cancer death in the Western world. Rectal 
cancer, defined as a tumour with its lower edge within 15 cm 
from the anal verge, accounts for about a third of all colorectal 
malignancies [1] and 98% of these are adenocarcinoma [2].
In the last decades, we have seen dramatic improvements in the 
outcomes  of  patients  with  rectal  cancer.  The  rate  of  local 
recurrence  has  decreased,  the  probability  of  survival  has 
increased,  and the quality  of  life  has improved.  Advances in 
surgical pathology, which have added to our understanding of 
the causes of locoregional recurrences, refinements in surgical 
techniques,  and  the  widespread  use  of  neoadjuvant  therapy 
(nCRT), have all contributed to these improvements.
However, advances in imaging have also played a pivotal role 
in identifying those at risk for recurrence, helping in planning 
surgical  procedures  and  selecting  patients  for  neoadjuvant 
therapy.
Adequate imaging is a fundamental component of rectal cancer 
management. 
Preoperative evaluation of the patient with rectal  cancer goes 
beyond  determination  of  tumour  stage.  Treatment  planning 
requires  not  only  defining  the  depth  of  tumour  invasion  in 
relation  to  the  bowel  wall  and  the  presence  of  metastatic 
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regional  lymph  nodes,  but  also  the  precise  relationship  of 
tumour to other pelvic structures such as the mesorectal fascia, 
the levator ani muscle, the anal sphincters, and adjacent organs. 
In  addition,  assessment  of  lymph  nodes  located  outside  the 
mesorectal fascia and in the retroperitoneum, liver and lungs, 
can provide  useful  information  that  may  affect  the  treatment 
strategy [3].
RECTAL ANATOMY
The rectum corresponds to the distal portion of the large bowel 
and it varies in length from 10 to 15  cm. It extends  from the 
upper end of the anal canal, at the level of the anorectal ring, a 
palpable anatomic landmark corresponding to the insertion of 
the  puborectalis  on  the  bowel  wall  to  the  recto-sigmoid 
junction, which is located from 12 to 15 cm from the anal verge. 
The rectum can be divided into three parts defined from the anal 
verge as lower rectum (0–6 cm), middle rectum (7–11 cm), and 
upper rectum (12–15 cm).The rectal wall is composed of three 
layers : mucosa, submucosa and muscolaris layer (with an inner 
circular  layer  and  a  outer  longitudinal  layer)  which  are  best 
visualized on ERUS.
Distally  the  rectum is  in  direct  contact  with  the  levator  ani 
muscles and this relationship must be taken into consideration 
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when deciding  between an abdominoperitoneal  excision  or  a 
sphincter-sparing  procedure  for  rectal  cancers  located  at  or 
below the level of the anorectal ring [2,3].
Besides it is important to assess the relationship with the anal 
sphincter and the intersphincteric space (Fig.1).
Fig.1 Rectum and anal canal:the image shows the three parts which form rectum,  
the three layers of the rectal wall and its relationship with levator ani muscle and  
anal sphincters.
 
The upper portion of the rectum is located above the anterior 
5
peritoneal reflection and is covered with peritoneum in the front 
and on both sides (Fig.2). Below the peritoneal reflection, the 
rectum is  completely  extraperitoneal  and fully  surrounded by 
mesorectum (derived from the dorsal mesentery of the hindgut) 
which contains lymph nodes, superior hemorroidal vessels and 
fibrous  tissue  and  it  is  bordered  by  a  thin  membrane  called 
mesorectal fascia.
Fig.2  Gross pathologic specimen of the rectum with crosssectional schematic of  
the  relationship  between the  CRM (black  line)  and peritonealised  portion  of  the  
rectum (red line).
The mesorectal fascia is an important barrier to the radial spread 
of  tumours  and  also  forms  the  plane  of  dissection  in  total 
mesorectal excision (TME).
The  mesorectum  is  thick  posteriorly,  where  it  has  a 
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characteristic bilobular appearance while anteriorly it is either 
absent (in  the upper intraperitoneal  portion of the rectum) or 
reduced to a thin layer of areolar tissue (in the mid and distal 
rectum). 
The mesorectal fascia is not as well defined anteriorly as it is 
posteriorly where it is separated from the urogenital organs by 
the Denonvillier’s fascia.
LOCAL STAGING OF RECTAL CANCER
The  diagnosis  is  usually  established  by  means  of  clinical 
examination  (rectal  digital  examination),  endoscopy 
(sigmoidoscopy  and  colonoscopy),  double-contrast  enema 
examination,  and  histologic  confirmation,  supplemented  by 
biochemistry  (eg,  blood  carcinoembryonic  antigen 
measurement). 
All  of  these  techniques  are  poor  indicators  of  the  depth  of 
invasion  and  lymph  node  involvement,  which  are  both 
important  features  for  prognosis.  Accurate  preoperative 
assessment of these prognostic factors is an important first step 
in assigning patients to one of the available treatment strategies.
From the clinical point of view, it is important to select patients 
for local therapy, such as transanal local excision or transanal 
endoscopic  microsurgery  (mainly  stage  T1  or  lower),  total 
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mesorectal  excision  (mainly  stages  T2  and  T3)  and 
preoperative CRT  aimed at downsizing and downstaging the 
tumor and at reducing the risk of local recurrence [4].
IMAGING EVALUATION IN STAGING OF RECTAL CANCER
Computed Tomography (CT)
CT is used for pre-operative assessment of distant metastases, 
but  don’t  have  a  role  in  local  staging  because  it  does  not 
distinguish rectal  wall  layers,  however it  can evaluate  lymph 
nodes  (mesorectal  but  also  iliac  and  mesenteric  or 
retroperitoneal) [5].
Endorectal Ultrasonography (ERUS)
ERUS has the advantage to visualize all layers of the rectal wall 
and  can  demonstrate  other  anatomical  structures,  such  as 
seminal  vescicles,  prostate,  cervix,  vagina,  blood vessels  and 
perirectal nodes situated into the field of view of the probe; also 
the  puborectalis  muscle  and  the  anal  sphincters  are  clearly 
visualized on ERUS [3].
On ERUS imaging, the rectal wall is visualized according to the 
Beynon five-layers model described below:
• first hyperechoic layer   - interface between the balloon and 
its contained water and the mucosal surface;
• second  hypoechoic  layer   -  mucosa  and  muscolaris 
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mucosae;
• third hyperechoic layer   – submucosa;
• fourth hypoechoic layer   – muscularis propria; 
• fifth hyperechoic layer   – interface between the muscularis 
propria and perirectal fat or serosa if present[6]. (Fig.3)
Fig.3 Beynon-five layers model.
Rectal  tumours  appear  as  expansions  of  the  first  hypoechoic 
layer  of  the  rectal  wall,  distorting  and  interrupting  the  other 
layers of the rectal wall from the inside out.
An ultrasound T classification, similar to the T classification of 
the AJCC TNM staging system is based on tumor disruption of 
the different echographic layers:
• the  uT1  tumor  (A)  is  characterized  by  the  partial 
erosion of the middle hyperchoic layer that corresponds 
to the submucosa;
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• the  uT2  tumor  (B)  is  characterized  by  the  complete 
disruption  of  the  submucosa  and  thickening  of  the 
hypoechoic  layer  that  corresponds  to  the  muscularis 
propria;
• the uT3 tumor (C) is characterized by the penetration of 
the tumor through the muscularis propria and into the 
perirectal fat;
• the uT4 tumor (D) is characterized by the involvement 
of adjacent organs, in this case the left seminal vesicle 
(Fig.4).
Fig.4 Ultrasound T classification.
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Metastatic lymph nodes appear as hypoechoic deposits, with an 
echogenicity  similar  to  that  of  the  primary  tumor.  They  are 
round rather than oval, with discrete or spiculated borders, and 
are  usually  found  adjacent  or  proximal  to  the  tumor.  Other 
features of metastatic lymph nodes are structural inhomogeneity 
and abnormal hilar echogenicity. 
ERUS is a very accurate tool for measuring size, circumference 
and distance of the tumor from various anatomic landmarks (eg, 
sphincters, prostate, etc), and it can delineate the relationship of 
distal  rectal  cancer  with internal  and external  anal  sphincters 
[3].
Magnetic Resonance Imaging (MRI)
The introduction of phased-array surface coils  and the use of 
T2-weighted fast spin echo thin-section sequences have enabled 
accurate  determination  of  prognostic  factors  and  anatomic 
assessment of the pelvis by delineating rectal tumors through 
increases  in  spatial  and  contrast  resolution  [7]  and  reducing 
times of acquisition.
MRI can accurately predict the depth of extramural penetration, 
and more importantly, predict the relationship between tumour 
and mesorectal fascia, which is an important risk factor for local 
recurrence.
T2-weighted  images  are  the  most  suitable  for  depicting  the 
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rectal wall anatomy, and MRI can distinguish:
• inner  hyperintense  layer   –  mucosa  and  submucosa  (no 
differention is possible between these two components);
• intermediate hypointense layer   – muscularis propria;
• outer hyperintense layer   – perirectal fat tissue (Fig.5) .
The mesorectal  fascia can be identified as a thin, low-signal-
intensity  structure  that  envelops  the  mesorectum  and  the 
surrounding perirectal fat.
Fig.5 Rectal wall layers identified by MRI.
The anal canal can be easily visualized in MRI of the lower 
rectum  with  clear  depiction  of  the  levator  ani  muscle,  the 
puborectalis  muscle,  and  the  internal  and  external  anal 
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sphincters. It is seen as a  cylindric structure that extends from 
the insertion of the levator ani muscle onto the rectum to the 
external anal margin [7].
On T2-weighted images, the tumour appears as epithelial-based 
thickening  with  a  signal  intensity  slightly  higher  than  the 
muscularis propria [5] (Figg.6,7).
Fig.6 T2-weighted FSE axial image of a T2 rectal tumour.
Fig.7 T2-weighted FSE axial image of a T3 rectal tumour.
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Metastatic lymph nodes appear as hypointense deposits into the 
mesorectal  fat,  and  the  use  of  border  contour  and  signal 
intensity characteristics in addition to size criteria can improve 
the accuracy of nodal staging [8].
Rectal MRI with phased-array coil provides a full evaluation of 
the rectal wall layers, mesorectal fat and fascia and it improves 
patient comfort compared with the use of an endorectal coil or 
ERUS.  Moreover,  stenosing  lesions  and  tumours  at  the 
rectosigmoid junction can be evaluated in all cases by MRI [7].
TNM STAGING
American  Joint  Committee on  Cancer (7th edition,2010) takes 
into account the subclassification of T3 tumors. Moreover, we 
can distinguish  between “T3 early” if  tumor  extends ≤5 mm 
beyond muscularis propria and “T3 advanced” if tumor extends 
>5 mm (Tab.1).
Depth  of  tumour  spread  beyond  the  rectal  wall  has  been 
validated as an important prognostic indicator. Tumours with 5 
mm or less of extramural spread regardless of node status have 
an  85%  cancer-specific  survival  rate  compared  with  poorer-
prognosis tumours with more than 5 mm spread, which have 
only a 54% 5-year cancer-specific survival rate. These tumours 
are  considered  a  high-risk  disease  and  can  benefit  from 
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preoperative-CRT. The MERCURY study showed that tumour 
spread  can  be  estimated  accurately  with  magnetic  resonance 
imaging (MRI) in comparison with pathologic results.
T staging
T1 Tumor invades mucosa and submucosa
T2 Tumor invades but does not penetrate muscularis propria
T3 Tumor invades subserosa through muscularis propria
T3a: tumor extends <1 mm beyond muscularis propria
T3b: tumor extends ≥1-5 mm beyond muscularis propria
T3c:  tumor  extends  >5-15  mm  beyond  muscularis 
propria
T3d: tumor extends ≥15 mm beyond muscularis propria
T4 Tumor  invades  peritoneal  reflection  (T4a)  or  other 
organs (T4b)
N staging
N0 No metastatic lymph nodes
N1 Metastasis in 1-3 perirectal nodes
N2 Metastasis in 4 or more perirectal nodes
M staging
M0 No distant metastasis
M1 Distant metastasis
Tab.1 AJCC TNM staging, 7th edition.
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SURGICAL TREATMENT
The recognition that involvement of the circumferential margin 
by tumour cells is important in local recurrences has led to the 
general  use of  total  mesorectal  excision  (TME) which at  the 
present  represents  the  surgical  approach  of  choice  for  rectal 
cancer because is able to reduce the local recurrence rate to less 
than 10% [9], improving the 5-year survival rate if compared 
with conventional surgery.
TME is achieved by means of a  precise, sharp dissection along 
the plane that separates the visceral from the parietal layers of 
the perirectal pelvic fascia, thus allowing radical removal of the 
rectum and its surrounding mesorectum [10].
The circumferential  resection margin  (CRM) is  the lateral  or 
radial  resection  margin  created  by the  surgeon and the  ideal 
plane of resection is just outside the mesorectal fascia.
These  advances  have  greatly  increased  the  importance  of 
accurate  preoperative  staging  in  providing  information 
regarding  tumor  location,  size,  configuration,  and  degree  of 
local  infiltration.  Knowledge  of  the  depth  of  tumour  spread 
through and beyond the bowel wall influences the selection of 
patients  who will  benefit  from preoperative  adjuvant  therapy 
while  reliable  spatial  information  on  the  tumour's  anatomic 
distribution may facilitate the planning of surgical therapy [10].
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RISK FACTOR FOR LOCAL RECURRENCE
In  large  databases,  the  risk  factors  associated  with  local 
recurrence are generally similar to the risk factors for distant 
recurrence: 
• T stage;
• N stage;
• distance to the CRM;
• perineural invasion;
• lymph node invasion;
• blood vessel invasion;
• histologic grade. 
Of these risk factors, the T and N stage are commonly used for 
neoadjuvant treatment decisions and, recently, also the distance 
to the CRM [11].
Incomplete removal of the lateral spread of the tumour is now 
generally accepted as the reason for most of local recurrences 
that may be reduced thanks to preoperative radiotherapy. 
In Europe there is a preference for preoperative radiotherapy, 
based on the results  of several  trials,  among which the most 
important is the Swedish Rectal Cancer Trial that showed the 
most  convincing results,  with a  local  recurrence rate  of  11% 
after radiotherapy compared with a rate of 27% in the controls, 
and improved survival [12].
Attention has also been directed at the surgical technique itself 
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as  a  determinant  of  local  recurrence  rates. Histology  of 
resection  specimens  has  shown  that  the  frequency  of  local 
recurrence  greatly  decreases  when  a  tumour-free 
circumferential  resection  margin  of  more  than  1  mm can be 
obtained.  Surgery alone should,  therefore,  be able to achieve 
local cure in virtually all T1 and T2 tumours and in many T3 
tumours. Preoperative radiotherapy could therefore be limited to 
patients  in  whom  an  involved  or  close  resection  margin  is 
expected,  if  these  patients  could  be  identified  by  a  reliable 
preoperative imaging method that predicted the distance of the 
tumour  from  the  circumferential  resection  plane  of  a  TME 
specimen.
Although the tumour stage is an important prognostic factor,
preoperative  assessment  is  of  little  benefit  when  it  does  not 
affect preoperative or operative management.
Prediction of the circumferential resection margin, by contrast, 
could  be  clinically  useful  to  select  patients  for  preoperative 
radiotherapy [13].
Tumour stage
Endorectal  ultrasound (ERUS) is very accurate for staging of 
superficial  rectal  tumours  but  is  not  as  useful  for  staging  of 
advanced  rectal  cancers,  so  it  is  the  gold  standard  for 
discriminating stage T1 from T2 [2].
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Instead MRI is very accurate for identifying large T3 and T4 
tumours and invasion of mesorectal fascia [4].
Most  staging  failures  with  MRI  occur  in  the  differentiation 
between  T1  and  T2 lesions  because  the  submucosal  layer  is 
generally not visualized on phased-array MRI.
As ERUS, MRI has some difficulty in determining between  T2 
and T3 lesions due to the  desmoplastic reaction. 
Nodal stage
Nodal disease is one of the most important risk factors for both 
local and distant recurrence, but identifying nodal involvement 
with imaging remains difficult because size criteria used on its 
own result inaccurate. 
In addition to size with 5 mm as a cut-off, the criteria which can 
provide addictional accuracy are:
• roundness,
• border irregularity,
• hypoehoic nature (ERUS)/ heterogeneus signal (MRI) 
[8].
Circumferential Resection Margin (CRM)
The  association  of  CRM  with  local  recurrence  was  first 
demostrated in 1986 by Professor Quirke’s group [14] and some 
trials have demonstrated that patients with CRM involvement 
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have 3.5 times the risk of local recurrence and double the risk of 
death [15].
The CRM is identified with the mesorectal fascia and a positive 
CRM is defined as a closed distance of 1 mm or less between 
tumour  and  resection  margin  and  it  can  be  the  result  of  an 
inadequate  total  mesorectal  excision  (TME)  surgery,  an 
advanced tumor that comes close to or invades the mesorectal 
fascia  or  of  an  inadequate  pre-operative  staging  and 
neoadjuvant therapy planning.
The mesorectal fascia is very difficult to identify with ERUS, 
except when there is an invasion of vagina, prostate, or seminal 
vesicles,  instead  many  single  center  studies  have  shown that 
MRI is highly accurate for the prediction of an involved CRM 
[1,11,13] (Fig.8 ).
Fig.8  MRI identification of mesorectal fascia.
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Materials and Methods
The aim of  this  study  is  to  evaluate  the  correlation  between 
endorectal ultrasound (ERUS) and magnetic resonance imaging 
(MRI) in preoperative staging of rectal cancer.
PATIENTS
From May 2011 to May 2013, fifty patients with biopsy proved 
rectal cancer were submitted to  MRI and  ERUS. All patients 
underwent  colonoscopic  examination  in  which  a  bioptic 
procedure was performed.
The inclusion criteria were:
1. histologically confirmed rectal adenocarcinoma,  
2. distal end of tumour located within 15 cm from the anal 
verge.
The characteristics of patients are summarized in table 2.
   VARIABLE                                            N
Gender 18 (36%) women
32 (64%) men
 Mean age 68.3 y (range 34-87 y)
Tab.2 Patients' characteristis.
Thirty-nine  patients  (78%)  underwent  to  preoperative 
chemoradiotherapy  (CRT)  followed  by  surgical  treatment, 
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instead  eleven  patients  (22%)  underwent  immediately  to 
surgical treatment (TME) without CRT. 
Following  surgery,  operative  specimens  were  analysed  by  a 
pathologist  and,  for  those  patients  who  underwent  surgical 
resection without pre-operative treatment, the surgical resection 
specimen was used as standard of reference for determination of 
depth of invasion (T stage) and perirectal nodal status (N stage).
MRI TECHNIQUES AND PARAMETERS
All MRI examinations were performed with a  3-Tesla scanner 
(Discovery 750, General Electric, Milwaukee, Wisconsin, USA) using a 
pelvic phased-array surface coil (8US TORSOPA). 
The night before the MR study, the patients were given a water 
enema  to  clean  the  rectum  and  the  examinations  were 
performed after luminal distension with rectal gel in a variable 
quantity  from  60  to  120  mL  relating  to  the  location  of  the 
lesion. It is important not to overdistend the rectum with rectal 
gel since this could distort the anatomy and reduce the ability to 
interrogate  the  surrounding  mesorectum,  which  would  be 
compressed by overdistension.
The patient is positioned supine, and the phased-array surface 
coil is placed on the pelvis in such a way that the lower edge of 
the coil lies below the pubic bone (Tab.3).
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Key elements of MRI technique
Strenght of magnetic field 3 Tesla 
Type of coil Pelvic  Phased-array  surface  coil 
(8US)
Rectal filling Yes (60-120 mL gel)
Rectal cleansing Yes  (the  night  before,  with  water 
enema)
Patient position Supine
Use  of  spasmolytics  to  reduce 
bowel motion artifacts 
No
Use of contrast medium No
Tab.3 MRI technique.
 The following sequences were acquired:
1. axial T2-weighted Fast Spin Echo (FSE) (repetition time 
[TR]/  echo  time  [TE]  3500-6000/  90-150  ms),  field  of 
view 24 cm,  section  thickness  5 mm,  interval  0.5  mm, 
matrix 384x224;
2. sagittal  T2-weighted Fast Spin Echo (FSE) (repetition 
time [TR]/ echo time [TE] 3500-6000/ 90-150 ms), field 
of view 24 cm, section thickness 5 mm, interval 0.5 mm, 
matrix 384x224;
3. coronal T2-weighted Fast Spin Echo (FSE) (repetition 
time [TR]/ echo time [TE] 3500-6000/ 90-150 ms), field 
of view 24 cm, section thickness 5 mm, interval 0.5 mm, 
matrix 384x224;
4. oblique-axial  T2-weighted  Fast  Spin  Echo  (FSE) 
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(repetition time [TR]/ echo time [TE] 3500-6000/ 90-150 
ms) on a plane perpendicular to the long axis of the tumor 
as visualized in the sagittal  sequences, field of view 22 
cm,  section  thickness  3  mm,  interval  0.2  mm,  matrix 
384x224;
5. sagittal  3D  T2-weighted  Fast  Spin  Echo  (CUBE) 
(repetition time [TR]/ echo time [TE] 1600/ 85-95 ms), 
field  of  view  24  cm,  section  thickness  0.9  mm,  no 
interspace, matrix 288x256;
6. axial  diffusion-weighted  (DWI) (repetition  time  [TR]/ 
echo time [TE] 2000-6000/ 50-55 ms), field of view 30-32 
cm, section thickness 5-6 mm; interval 1-1.2 mm; b-value 
0-500-800 sec/mm2 (Tab.4).
The overall acquisition time varied between 20 and 30 minutes.
MRI protocol
1 Axial T2-weighted FSE (section thickness 5mm, interval 0,5mm)
2 Sagittal  T2-weighted  FSE (section  thickness  5  mm,  interval 
0.5mm)
3 Coronal T2-weighted FSE (section thickness 5 mm, interval 0,5 
mm)
4 Oblique-axial  T2-weighted  FSE (section  thickness  3  mm, 
interval 0,2 mm)
5 Sagittal  3D  T2-weighted  FSE  (CUBE) (section  thickness  0,9 
mm, no interspace)
6 Axial Diffusion Weighted (DWI)
Tab.4 MRI protocol.
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MR IMAGES ANALYSIS
All  MR  examinations  were  interpreted  by  two  experienced 
gastrointestinal  radiologists  blinded  to  each  other  and  to  the 
endosonographic findings.
The following features were described:
• lesion site (distance from the anal verge);
• tumour longitudinal extent;
• maximum thickness of the lesion;
• distance between lesion and puborectalis muscle;
• levator ani muscles infiltration; 
• depth of extramural spread;
• distance between lesion and mesorectal fascia;
• overcoming of the anterior peritoneal reflection;
• mesorectal,  iliac  and  obturatory  lymph  nodes 
involvement;
• pelvic organs infiltration.
Local  MR  staging  was  established  according  to  the  TNM 
system. 
Positive (N1-N2) lymph nodes were considered if :
• greater than 5mm in diameter;
• irregular border;
• mixed-signal intensity.
The mesorectal  fascia was demostated as a low-intensity  fine 
structure enveloping the mesorectum. 
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ERUS TECHNIQUES AND PARAMETERS
ERUS was performed by an experienced operator, using a Pro 
Focus  BK Medical  ultrasound  machine  with  a  rigid rotating 
probe (Type  2050) and  a  6/16  MHz  transducer (BK  Medical,  
Wilmington, Massachusetts, USA) that provided a 360° radial scan 
of the rectal wall and surrounding structures. 
All  patients  received an enema to clean the rectum the night 
before the examination.
The procedure was performed with patients in the left  lateral 
decubitus  position  without  sedation.  A  digital  rectal  and 
proctoscopic examination was performed to assess the distance 
from  the  anal  verge  and  the  longitudinal  extent. The 
proctoscope permitted the passage of the ultrasound probe to 
facilitate  positioning  of  the  probe  above  the  lesion;  this 
facilitated  complete  imaging  of  the  lesion  from  its  most 
proximal  to  distal  extend  as  well  the  proximal  mesorectum, 
which may harbor involved lymph nodes.
The transducer rotated inside the head of the probe to provide a 
360° field of view. The  advantage of 3D ERUS was that the 
volume  could  be  freely  rotated,  rendered,  tilted  and  sliced, 
providing  the  operator  with  an  infinite  variety  of  section 
parameters,  as  well  as  visualization of  the  lesion at  different 
angles and in different planes (coronal, frontal, axial)  (Tab.5). 
Multiplanar reformatting was probably the most useful way to 
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demonstrate the adjacent structures in several planes ( Fig.9 ).
Key elements of ERUS technique
Type of probe Rigid  rotating  probe  (Type  2050) 
providing a 360°field of view with the 
advantages of 3D ERUS. 
Type of transducer 6/16 Mhz 
Rectal cleansing Yes  (the  night  before,  with  water 
enema)
Digital rectal and proctoscopic 
examination
Yes,  to  assess  the  distance  from the 
anal verge and the longitudinal extent 
and  to  permit  the  positioning  of  the 
probe above the lesion
Patient position Left lateral decubitus without sedation
Tab.5 ERUS technique.
Fig.9 View of rectal wall layers with 3D ERUS.
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ERUS IMAGING ANALYSIS
All ERUS examinations were performed by a single operator, 
who evaluated  the following features:
• lesion site (distance from the anal verge);
• tumour longitudinal extent;
• distance  between  lesion  and  puborectalis 
muscle;
• levator  ani  muscles  (puborectalis  muscle) 
infiltration; 
• depth of extramural spread;
• mesorectal lymph node involvement;
• pelvic organs infiltration.
On ERUS imaging, rectal tumours appear as expansions of the 
first  hypoechoic  layer  of  the  rectal  wall,  distorting  and 
interrupting the other layers of the rectal wall from the inside 
out.
The sonographic criteria for identifying involved lymph nodes 
consist in:
• size greater than 5mm;
• mixed signal intensity;
• irregular margins;
• spherical rather than ovoid or flat shape.
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STANDARD OF REFERENCE
For  patients  who  proceeded  directly  to  surgical  resection 
without  neoadjuvant  therapy  (n=11),  the  surgical  resection 
specimen was used as standard of reference for determination of 
depth of invasion (T stage) and perirectal nodal status (N stage).
Pathological examination was done without knowledge of the 
results  of  ERUS  and  MRI,  and  the  surgical  specimen  was 
staged  (TNM,Tab.1) according  to  the  guidelines  of  the 
American Joint Commitee on Cancer (AJCC).
STATISTICAL ANALYSIS
1. The  correlation  between  MRI  and  ultrasound data  was 
calculated  for  each  parameter  using  two-tailed 
Spearmanʼs rank-order correlation coefficient (rs) and 
a  p-value  of  less  than  0.05  was  considered  statistically 
significant.
2. The interobserver  agreement  for  MR imaging  was 
assessedby using the Cohen’s kappa statistics. 
Kappa values were interpreted in the way showed in table 6, as 
proposed by Landis et al. [16].
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K values Degree of agreement
0 Absence of agreement
0,2 Slight agreement
0,21-0,40 Fair agreement
0,41-0,60 Moderate agreement
0,61-0,80 Substantial agreement
0,81-1 Almost perfect agreement
Tab.6 Landis' interpretation of K value.
Confidence limits were set at 95 percent.
Descriptive statistics were also used.
All calculations were done by using SPSS statistical software 
(SPSS Inc, Chicago, Ill, USA).
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Results
From May 2011 to May 2013, fifty  patients  (39 treated with 
neoadjuvant  chemoradiotherapy  followed  by  surgery  and  11 
with  surgical  resection  alone)  were  evaluated  with  MRI  and 
ERUS. 
The characteristics of patients are described in table 2 while the 
characteristics of tumours are described in table 7.
             VARIABLE               N
Distance from anal verge 8,26±2,87cm (range 2-
14 cm)
Location
• upper third of rectum
• middle third of rectum
• lower third of rectum
11 (22%)
29 (58%)
10 (20%)
Location  in  relation  to  peritoneal 
reflection
42  (84%)  were  below 
the peritoneal reflection
Pathological  T  stage  of  11  patients  who 
underwent to surgery alone
• pT2
• pT3
• pT4
4
6
1
N+ 8 patients
Tab.7 Tumours' characteristics.
Patient acceptance of ERUS and MRI was good in all cases, and 
there were no complications.
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CORRELATION BETWEEN ERUS AND MRI
ERUS data and MRI data of  reader A, showed a statistically 
significant  correlation  for  the  lesion  site (rs=0.873, 
p<0.000001),  the  tumour  longitudinal  extent (rs=0.378, 
p=0.010393),  the  distance  between lesion  and puborectalis 
muscle (rs=0.7954, p<0.000001) and the depth of extramural 
spread (rs=0.5107, p=0.000149).
Also,  ERUS  data  and  MRI  data  of  reader  B revealed  a 
statistically significant correlation for the lesion site (rs=0.8485, 
p<0.000001),  the  tumour  longitudinal  extent (rs=0.3794, 
p=0.010131),  the  distance  between lesion  and puborectalis 
muscle (rs=0.7989, p<0.000001) and the depth of extramural 
spread (rs=0.5046, p=0.000186).
Moreover,  ERUS  and  MRI  were  able  to  demonstrate  the 
levator ani muscles infiltration with an overall agreement of 
82%  for  reader  A and  80%  for  reader  B,  the  lymph  node 
involvement with an agreement of 68% for reader A and 76% 
for  reader  B and  the  pelvic organs  infiltration with  an 
agreement of 80% for both readers.
These correlation are scheduled in table 8.
32
TRUS-MRI reader A TRUS-MRI reader B
Lesion site rs=0.873
p<0.000001  
rs=0.8485
p<0.000001
Tumour longitudinal 
extent
rs=0.378
p=0.010393
rs=0.3794
p=0.010131
Distance  lesion-
puborectalis muscle
rs=0.7954
p<0.000001
rs=0.7989
p<0.000001
Depth of extramural 
spread
rs=0.5107
p=0.000149
rs=0.5046
p=0.000186
Levator  ani  muscle 
infiltration
82,00% 80,00%
Lymph  node 
involvement
68,00% 76,00%
Pelvic  organs 
infiltration
80,00% 80,00%
Tab.8 Correlation between ERUS and MRI.
MRI INTEROBSERVER AGREEMENT
The interobserver agreement between MRI readers A and B was 
almost perfect for the lesion site (k=0,91; 95% CI: 0,882-0,937) 
and the distance between lesion and puborectalis muscle (k= 
0,914; 95% CI: 0,878-0,950).
There was a substantial agreement for the tumour longitudinal 
extent (k=  0,791;  95%  CI:  0,700-0,882),  the  depth  of 
extramural spread (k= 0,758; 95% CI: 0,672-0,844) and the 
maximum thickness of the lesion (k= 0,734; 95% CI: 0,625-
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0,844). 
Instead there was only a moderate agreement for the  distance 
between  lesion  and  mesorectal  fascia (k=  0,48;  95%  CI: 
0,312-0,649).
There  was  also  an  agreement  between  the  two  observers  of 
100%  for  the  pelvic  organs  involvement,  of  96%  for  the 
overcoming of the anterior peritoneal reflection, of 88% for 
the mesorectal lymph nodes involvement and of 82% for the 
levator ani muscles infiltration.
These results are scheduled in table 9.
                MRI interobserver agreement
Almost 
perfect 
0.81<k<1
• Lesion site
• Distance lesion-puborectalis muscle
Substantial
0.61<k<0.80
• Tumour longitudinal extent
• Depth of extramural spread
• Maximum thickness of lesion
Moderate
0.41<k<0.60
• Distance between lesion and mesorectal fascia
100,00% • Pelvic organs involvement
96,00% • Overcoming of the anterior peritoneal reflection
88,00% • Mesorectal lymph nodes involvement
82,00% • Levator ani muscles infiltration
Tab.9 MRI interobserver agreement.
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DISTANCE BETWEEN TUMOUR AND MESORECTAL 
FASCIA
The relationship between tumour and mesorectal fascia is an 
important risk factor for local recurrence, but  its involvement 
can correctly visualized only on MRI.
In our study the mesorectal fascia was visualized on MRI in all 
patients.
For  MRI  observer  A the  mean  distance  between  lesion  and 
mesorectal  fascia  was  0.74  cm  (range,  0-2.2  cm),  and  for 
observer B it was 0.59 cm (range, 0-1.8 cm).
The distance between lesion and mesorectal fascia was <5 mm 
in seventeen patients (34%) for MRI  reader A and in twenty-
two  patients  (44%)  for  MRI  reader  B with  a  moderate 
interobserver agreement.
AGREEMENT  BETWEEN  MRI/ERUS  AND 
HISTOLOGIC EXAMINATION (HE)
Eleven patients underwent to surgical resection alone and the 
agreement between MRI and histologic examination (HE) was 
45.5% for T stage and 63.6% for N stage, instead the agreement 
between  ERUS and histologic  examination was 27.3% for  T 
stage and 63.6% for N stage.
T stage was overestimated in 7 cases (63.6%) with ERUS and 
35
in  6  cases (54.5%) with MRI,  and it  was  underestimed in 1 
cases  (9.1%)  with  ERUS  and  in  any  case  with  MRI 
(Tabb.10,11).
N stage was overestimated in 3 cases (27.3%) with ERUS and 
MRI, and it was underestimed in 1 cases (9.1%) with ERUS and 
MRI.
Tab.10  Agreement  between  MRI  and  histologic  examination  for  T  stage:the  
yellow boxes represent the 5 cases (45,5%) of agreement between imaging and the  
reference  standard  while  the  green  boxes  represent  the   6  cases  (54.5%)  of  
overstaging by MRI.
Tab.11 Agreement between ERUS and histologic examination of T stage: the yellow 
boxes represent the 3 cases (27.3%) of agreement between imaging and the standard of reference, the 
green boxes represent  the 7 (63.6%) cases of overstaging and the blue box represents the 1 case 
(9.1%) of understaging by ERUS. 
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Discussion
The correct staging of rectal cancer is of high relevance since 
the treatment options depend on the stage at presentation.  The 
common practice  (on the basis of oncologic guidelines)  is  to 
administer  neoadjuvant  therapy followed  by  surgery  to 
patients with T3 and T4 tumours or any tumour with positive 
locoregional lymph nodes N+, instead patients with T2 tumours 
are treated with surgical resection (TME) and T1 tumours may 
be  correctly  resected  either  by  endoscopic  techniques 
(mucosectomy)  or  minimally  invasive  surgical  procedures 
(transanal endoscopic microsurgery,TEM).
Although  rectal  tumours  can  be  diagnosed  using  digital 
examination, barium enema, and colonoscopy/ sigmoidoscopy, 
these  endoluminal  techniques  do  not  provide  sufficient 
information  about  the  extraluminal  spread  of  the  tumour  for 
preoperative planning. Therefore  CT,  ERUS and MRI are the 
imaging modalities predominantly utilized in the preoperative 
staging of rectal cancer. 
CT is unable to differentiate the different layers of the rectal 
wall and has lower overall predictive accuracy than ERUS and 
MRI in locoregional staging, however it is used to search for 
distant metastasis (e.g. lung, liver).
Bipat et  al.  [4] published an extensive meta-analysis in 2004 
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comparing  ERUS,  CT and  MRI,  including  a  variety  of  MR 
techniques  and  coils:  they  found  that  ERUS  was  the  best 
technique  for  assessing  local  invasion,  with  a  sensitivity and 
specificity of detecting muscularis propria invasion of 94% and 
69% for MRI and, 94% and 86% for ERUS and a sensitivity 
and specificity  of  detecting  perirectal  tissue invasion of  82% 
and 76% for MRI and, 90% and 75% for ERUS.
Later,  in  2013,  Beaumont  et  al.  [17]  compiled  the  results  of 
several large studies (n=40 or greater) and suggested that ERUS 
was significantly more sensitive than MRI for the assessment of 
T1  and  T2  with  no  significant  difference  between  the  two 
modalities in the staging of T3 and T4 tumours. In fact it has 
been  demonstrated  that  the  most  staging  failures  with  MRI 
occur  in  the  differentiation  between  T1  and  T2  lesions  and 
between  T2  and  “T3  early”  lesions.  A  T1  tumor  cannot  be 
reliably distinguished from T2 because the submucosal layer is 
generally not visualized on phased-array MRI and the difficulty 
in determining T2 from “T3 early” lesions is often caused by 
the  presence  of  desmoplastic  reaction  within  the  peritumoral 
tissues  that  made  difficult  the  MRI  differentiation  between 
perirectal fat spiculation, caused  by fibrosis alone from those 
containing tumour cells. 
ERUS has the same difficulty  in distinguishing T2 from “T3 
early”, and this often involves an overstaging [13].
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In  our  study,  considering  only  the  eleven  patients  who 
underwent surgery without CRT, T stage was overestimated  in 
7 cases (63.6%) with ERUS and in 6 cases (54.5%) with MRI; 
in particularly ERUS has not been able to distinguish T2 from 
T3  in  3  cases  (42.9%)  and  MRI  in  2  cases  (33.3%). 
(Tabb.10,11).
Distinguish  between  T2  from  T3  tumours  at  the  immediate 
interface between the muscle coat and the extramural fat is of 
little  importance  in  preoperative  clinical  decision  making 
because  the  outcome  of  patients  with  “early  T3”  tumours  is 
good with surgery alone [10], instead is important  to evaluate 
the depth of extramural spread in tumours that are clearly T3, 
whether or not the  tumour threatens the mesorectal fascia, 
whether the tumour has any other  markers of aggressiveness, 
such  as  nodal  metastases,  vascular invasion or  local 
peritoneal  involvement,  because  they  are  important  in 
determining prognosis and stratifying patients for preoperative 
therapy [18].
Gollins et al. [19] in a recent paper suggested that reduction of 
rectal cancer local recurrence has not had any significant impact 
on  distant  metastatic  relapse  that  is  now the  major  cause  of 
death.  Features  on  histological  examination  of  resected 
specimens  predict  increased  risk  of  postoperative  systemic 
recurrence, including: 
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• more  than  5  mm  invasion  of  disease  through  the 
muscularis propria into the mesorectum (T3c);
• extra-mural vascular invasion (EMVI) ; 
• and lymph node involvement.
For patients with such features, with optimum surgery and
selective use of preoperative radiotherapy, distant metastatic
relapse is about six-fold greater than local recurrence
(about 30% versus 5%)   and is now the main cause of death. 
MRI scanning is  the pretreatment investigation that  can most 
reliably  identify  such  features.  MRI-detected  EMVI is  the 
serpiginous  extension  of  the  tumour  signal  within  a  vascular 
structure. It has been found that the severity of MRI-detected 
EMVI correlates with relapse-free survival and on the basis of 
previous studies  Sohn et al. [20] hypothize that MRI-detected 
EMVI  could  predict  distant  metastasis.  In  particular,  EMVI 
involving a large vessel (≥3 mm) had a higher risk than EMVI 
involving a small vessel. 
Preoperative  identification  of  distant  metastasis  is  important 
because patients  with synchronous metastasis  should undergo 
different  treatment,  such  as  neoadjuvant  chemotherapy  or 
metastasectomy. Recent studies indicated a role for induction 
chemotherapy in patients with locally advanced rectal cancer as 
an  alternative  to  preoperative  chemoradiation,  because  it  can 
eradicate  micrometastasis  by  the  delivery  of  a  full  systemic 
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dose.
Tumours with 5 mm or less of extramural spread regardless of 
lymph node status have an 85% 5 year cancer-specific survival 
rate compared with poorer prognosis of tumours with more than 
5 mm spread, which have only a 54% 5 year cancer-specific 
survival rate [21].
Unfortunately our study did not demonstrate an high accuracy 
of  preoperative MRI or ERUS in the prediction of correct  T 
stage,  since  the  agreement  with  histopathology  was  about 
45.5% for MRI and only 27.3 for ERUS and it did not correlate 
with the data reported in the most of the studies published in 
literature (65%-100%) [22].
The single most important  element in the realization of local 
control is a free circumferential resection margin (CRM) and 
Quirke  et  al.  [14]  already  in  1986  demonstrated  that 
microscopically inadequate radial margins lead to a recurrence 
rate of 86% and many subsequent studies have confirmed the 
importance of a free CRM.
It  has  been  suggested  that  circumferential  resection  margin 
status  is  even more informative in treatment planning than T 
stage, so the currently TNM classification, based on depth of 
bowel  infiltration,  does  not  distinguish  between  primary 
resectable tumours and locally advanced tumours. Infact a T3 
tumor can be either primary resectable with a wide tumor-free 
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CRM or locally advanced with a close or involved CRM [23].
For  the prediction of  the CRM, the  radiologists  assessed the 
MRI scans for the shortest distance from the outermost part 
of  the  tumour  to  the  adjacent  mesorectal  fascia [13],  so 
positive margins can be due to:
• main tumor extension;
• tumour deposits;
• extramural vascular invasion; 
• suspicious lymph nodes [24].
Beets-Tan  et  al.  [13]  in  a  study  of  preoperative  MRI  in  76 
patients,  concluded  that  a  tumour-free  zone  of  1  mm  by 
histology  could  be  predicted  with  a  high degree  of  certainty 
when the measured distance on MRI was at least 5 mm, and a 
histological  margin of at  least  2 mm when the MRI distance 
was at least 6 mm.
Histology of resection specimens has shown that the frequency 
of local recurrence greatly decreas when a tumor- free CRM of 
more than 1 mm can be obtained.
With ERUS it is very difficult to identify the mesorectal fascia 
in  patients  with  a  “threatened  CRM,”  except  when  it  shows 
invasion of vagina, prostate, or seminal vesicles. Many single-
center studies have shown that MRI is highly accurate for the 
prediction of an involved CRM [13].
Granero-Castro et al. [25] published the results of a work which 
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aim was to evaluate  the accuracy of ERUS in predicting the 
pathologic CRM in low rectal anterior tumours and to compare 
it with MRI findings. When focusing on low rectal tumours, the 
overall  accuracy of endorectal ultrasound increased to 87.5%, 
whereas  the  accuracy  of  MRI  decreased  to  87.5%,  with  a 
negative  predictive  value  of  95.6% for  both  diagnostic  tests. 
The limitations of this study were due to the small sample size 
and   to  the  fact  that  interobserver  variability  in  radiologic 
assessment  was  not  evaluated.  Anyway  they  suggested  that 
ERUS can help MRI in predicting CRM involvement in mid to 
low anterior  rectal  cancer,  especially  at  the  low third  of  the 
rectum, with a high negative predictive value.
As  regards  low rectal  cancer  a  curative  restorative  resection 
requires  both  the  mesorectal  fascia  plane  and  the 
intersphincteric plane to be clear of tumor. If tumour invades
the  intersphincteric  plane,  sphincter  excision  is  needed  to 
achieve  a  clear  pCRM.   An  MRI  staging  system  to  assess 
tumour-intersphincteric plane relationship has been developed 
and this staging system has been prospectively validate in the 
MERCURY II study [26].
The  primary  aim  was  to  reduce  low  rectal  cancer  pCRM 
involvement  to  less  than  15%  by  using  MRI  planning  to 
determine  the  relationship  of  tumour  to  both  the  mesorectal 
fascia  and  the  intersphincteric  plane.  By  combining  the 
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previously validated assessment of the mesorectal  fascia with 
intersphincteric  plane staging radiologists  were able to assess 
the  entire  low rectal  cancer  plane.  Combined  staging  of  the 
intersphincteric  plane  and  the  mesorectal  fascia  plane  was 
termed  MRI  low  rectal  plane  (mrLRP).  The  MERCURY  II 
study  suggests  that  mrLRP  can  reliably  assess  the  extent  of 
tumour invasion and predict for pCRM involvement in order to 
appropriately  select  the  correct  treatment  plane.  The  study 
findings indicate that mrLRP reporting is required for all low 
rectal cancers.
Lymph nodes assessment remains an unresolved problem in 
the  preoperative  staging of  rectal  cancer  for  both  ERUS and 
MRI. In the meta-analysis of Bipat et al. [4], the sensitivity and 
specificity of detecting lymph nodes involvement was 66% and 
76% for MRI and, 67% and 78% for ERUS. 
Although  short  axis  diameter  greater  than  5  mm  was  the 
criterion most commonly used to predict lymph node metastases 
on  MRI,  our  review  found  little  evidence  to  support  this 
particular cut-off and Brown et al. [8] suggested that the use of 
border contour and signal intensity characteristics, in addition to 
size criteria, can improve the accuracy of nodal staging. 
Our  study,  considering  only  the  11  patients  who  underwent 
surgery without CRT, addresses an overall agreement for lymph 
nodes involvement of 63.6% for ERUS and MRI. 
44
In a recent meta-analysis Li et al. [27] suggested that MRI at a 
high field strength improves the diagnostic accuracy for lymph 
nodes  evaluation  in  addition  to  DWI images,  so  MRI is  the 
recommended method for lymph nodes evaluation.
Due  to  its  wide  field  of  view,  MRI  can  also  predict  the 
peritoneal  involvement,  that  represents  an  independent  risk 
factor for intraperitoneal recurrence after surgery. 
Moreover, the identification of the peritoneal attachment and its 
involvement  is  important  because  tumours  with  peritoneal 
reflection invasion (T4a) are treated as colon cancers and these 
tumours should be reported at MR imaging as circumferential 
resection margin (CRM) negative because CRM corresponds to 
the  cut  of  surgical  resection  margin  and  does  not  cover  the 
anterior aspect of the upper rectum [24,28]. 
In  our  study,  ERUS and MRI have  a  statistically  significant 
correlation for:
• assessment of lesion site;
• tumour longitudinal extent;
• distance between lesion and puborectalis muscle;
• depth of extramural spread.
There  is  also an overall  good agreement  for  the  levator  ani 
muscles  infiltration,  the  mesorectal  lymph  nodes 
involvement and the pelvic organs infiltration (Tab.8).
MRI also allowed to evaluate:
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• maximum thickness of the lesion; 
• distance between lesion and mesorectal fascia; 
• overcoming of the anterior peritoneal reflection;
• iliac and obturatory lymph nodes involvement.
Although,  ERUS  can  distinguish  tumour  T1  stage  from  T2 
because it shows all the different layers of the rectal wall, it is 
operator  dependent  and  requires  a  learning  curve  for  correct 
staging of rectal cancer.  Moreover, the accuracy of ERUS in 
the  staging  of  rectal  cancer  has  been  highly  variable,  with 
values ranging anywhere from 69%-89%. 
The study of Harewood et al. [29] on the potential biases have 
showed an inverse relationship between study size and reported 
ERUS accuracy, as well as higher reported accuracy values in 
older  studies  and   this  study  also  noted  that  most  published 
studies utilized very experienced operators, so actual accuracy 
of  ERUS  is  probably  lower  in  common  practice  than  in 
publication.  ERUS cannot  assess  stenotic  tumours  or  lesions 
located in the upper rectum and it cannot visualize mesorectal 
fascia and tumour extension into surrounding organs because of 
the limited field of view.
Anyway,  ERUS  allows  to  identify  those  patients  who  are 
candidate  for  local  excision since  it  is  superior  in  the 
identification of early rectal  cancer;  furthermore it's  useful to 
evaluate  tumour  size  and  distance  from  anal  verge  and  it's 
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superior in identifying the involvement of anal sphincter.
ERUS has a vital role in determining radical or local excision 
based  on  identification  of  T-stage.  Transanal  endoscopic 
microsurgery  (TEMs)  has  a  reduced  morbidity  and  mortality 
compared with radical surgery. TEMs only confers oncological 
equivalence with TME in noninvading tumours and only has a 
role in defined small cancers with no evidence of invasion into 
the muscularis propria. Its role in patients with pathological or 
clinical uncertainty with regard to the depth of invasion should 
be  diagnostic  with  the  knowledge  that  subsequent  salvage 
surgery might be required. Correct identification of lesions that 
can be managed with TEMs is therefore imperative. ERUS has 
a 100% specificity in determining that a lesion is limited to the 
mucosa or submucosa and this fact aids in the  assessment of 
lesions that are being considered for submucosal resection [30-
32].
Endorectal MRI has the same limitations of ERUS and it has 
been  almost  completely  replaced  by  phased-array  coils  that 
have  made  better  spatial  resolution  with  improved  signal-to-
noise ratio, without the limitations of endorectal MRI and they 
have  the  advantage  of  having  a  larger  field  of  view  of  the 
mesorectal fascia [33].
Burbach et al. [34] recently published a paper  providing crucial 
information  for  development  of  MRI-guided  GTV  (Gross 
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Tumour Volume, in other words the area corresponding to the 
tumour  itself)  boost  strategies complementary  to  standard 
chemoradiation in order to optimize neoadjuvant strategies and 
organ  preservation.  Agreement  between  GTV  delineations 
performed  by  the  different  observers  was  good  and  was 
comparable between different MRI sequences. This study used 
T2-weighted images, DWI images and DWI SPLICE sequence 
which  was  specifically  designed  to  acquire  geometrically 
undistorted images. The best consistency was reached on DWI 
images.Their results indicate that MRI-based GTV-delineation 
is  feasible  for  boost  purposes  as  long  as  DWI is  optimized, 
experience  is  sufficient,  and  consensus  is  reached  between 
multiple observers.
Downsides  of  MRI  remain  the  limited  availability,  the  high 
cost,  the  need  to  obtain  good  standard  high-resolution 
sequences,the interpretation of the images that depends on the 
knowledge  and  expertise  of  the  radiologist  [35]  and  the 
possibility of patients' contraindications.
With routinary use of MRI, approximately 40-50% of patients 
can  be  treated  successfully  with  primary  surgery  without 
significant risk of local recurrence or systemic failure. For the 
remaining  patients,  the  use  of  preoperative-CRT is  aimed  at 
reducing the size of the primary tumour and making irresectable 
tumour resectable with tumour free circumferential margins to 
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reduce the risk of recurrence [28]. 
In table 12 are summarized the positives and the downsides of 
each technique.
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MRI ERUS
Costs High Low
Availability Radiology department Doctor's office
Patients controindications Pacemakers,  metal 
implants, claustrophobia
None
Anatomic resolution Good Excellent
Tissue resolution Excellent  (potentially 
improved by DWI, DCE)
Good
Anatomic coverage Wide Narrow
Operator dependency High Very High 
Early cancers T1 vs. T2 Poor Good
T1/T2  vs. T3 Good Good
T4 Excellent Only anterior tumors
Mesorectal nodes Moderate Moderate
Infiltration  of  levator 
muscle ani
Good Moderate
Infiltration  of  anal 
sphincter
Moderate Good
Tumours of upper rectum Assessed Not assessed
Stenotic tumours Assessed Not assessed
Depth  of  extramural 
spread
Slightly superior
Extramural  vascular 
invasion
Assessed Not assessed
Peritoneal involvement Assessed Not assessed
Iliac  and  Obturatory 
lymph nodes
Good Poor 
Relation  to  Mesorectal 
fascia
Excellent Poor
Possibility  for  a  MRI-
guided RT boost
Yes No
Tab.12 Positives and downsides of MRI and ERUS.
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Conclusions
With  the  development  of  the  technique  (faster  acquisitions, 
dedicated  external  coils,  contrast  agents,  etc.),  MRI  has 
achieved almost the same accuracy as ERUS for local staging of 
rectal cancer. 
In this study comparing those two modalities we can state that 
phased-array MRI is slightly superior in determining the depth 
of  transmural  tumour  invasion (T stage)  and it  has  the same 
value in detecting lymph node metastasis (N stage) as compared 
to ERUS (Tabb.10,11).
MRI has also an additional value in the preoperative evaluation 
of  other  markers  of  tumour  aggressiveness  such  as  iliac  and 
obturatory  nodal  involvement,  overcoming  of  the  peritoneal 
reflection,  extramural vascular  invasion  and  especially  the 
involvement  of  the  mesorectal  fascia,  which  represents  the 
CRM. 
In conclusion, there was a very good intermodality agreement 
between  ERUS and  MRI and because  the  extramural  spread 
(with regard to CRM status, in particular) is the most important 
prognostic  indicator  with  regard  to  T  stage, we  suggest  the 
routinary use of MRI for the staging of rectal cancer with the 
use of ERUS only in preoperative staging of patients with early 
tumours (T1-T2) who can be avoided from unnecessary TME. 
Furthermore  ERUS  is  good  in  the  identification  of  anal 
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sphincter involvement and its accuracy in the staging of mid-
low anterior rectal cancer is high so that it can helps MRI in the 
assessment of these tumours. 
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